SSI: Revolutionizing Breast Cancer Detection, but Slowly
Building off conventional ultrasound technology, France's SSI hopes to change the way breast cancer detection is done, reducing the number of unnecessary biopsies by employing elastography to register the stiffness of breast tissue. But as the company seeks to challenge a 3000 year old, low tech approach--manual palpation--company officials are proceeding slowly and are cautious about the claims they make for their technology's innovativeness.
You may also be interested in...
Surgeons attending the 11th annual meeting of the American Society of Breast Surgeons were perplexed by the reversal of the trend away from mastectomy and toward breast-conserving therapies. Advanced breast-conserving products were presented at the meeting; but with lowered revenue expectations that can ultimately be attributed to the economic woes of the past couple of years. High unemployment and the lack of health care coverage have prompted many women to delay or forego their yearly mammogram, and as a result, the numbers of biopsies, surgeries, and radiation therapy procedures have declined as well.
Mammography coverage policies among public and private payers are not likely to be restricted, at least in the near term, by the U.S. Preventive Services Task Force's new breast cancer screening guidelines, but prospects for longer-term adjustments remain
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.